SCHEMBL7916416

SCHEMBL7916416

COc1ccc(C(O)CN)cc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.57
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
SMPD1 P17405 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
F2 P00734 2/20 0.49
F10 P00742 2/20 0.49
PRSS1 P07477 2/20 0.49
F7 P08709 2/20 0.49
PRSS2 P07478 1/20 0.49
F3 P13726 1/20 0.49
PRSS3 P35030 1/20 0.49
KMT2A Q03164 2/20 0.48
BCHE P06276 1/20 0.47
AMY1A P0DUB6 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30352666 1.00 NFKB1 (0.57) NFKB1BLMPMP22SMPD1HDAC1
SCHEMBL9070525 0.92 NFKB1 (0.48) NFKB1BLMPMP22F2F10
SCHEMBL7148513 0.92 NFKB1 (0.48) NFKB1BLMPMP22F2F10
SCHEMBL8843624 0.89 SMPD1 (0.53) SMPD1HDAC1HDAC8HDAC6F2
SCHEMBL7919807 0.89 NFKB1 (0.51) NFKB1BLMPMP22SMPD1HDAC1
SCHEMBL7919811 0.87 NFKB1 (0.55) NFKB1BLMPMP22
SCHEMBL9586284 0.86 SMPD1 (0.56) SMPD1HDAC1HDAC8HDAC6F2
SCHEMBL2060104 0.86 SMPD1 (0.56) SMPD1HDAC1HDAC8HDAC6F2
SCHEMBL24162320 0.85 SMPD1 (0.49) BLMSMPD1HDAC1HDAC8HDAC6
SCHEMBL17024332 0.85 FFAR4 (0.51) NFKB1BLMPMP22MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3777979-B1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) 2024-01-17 EP disclosed
EP-3777979-B1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) 2024-01-17 EP disclosed
CN-110407741-B Anti-inflammatory compound and preparation and application thereof 启元生物(杭州)有限公司 2023-03-21 CN disclosed
US-11440886-B2 Anti-inflammatory compound, and preparation and use thereof E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (CN) 2022-09-13 US disclosed
EP-3777979-A1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF Vivavision Biotech, Inc. (CN) 2021-02-17 EP disclosed
EP-3777979-A1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF Vivavision Biotech, Inc. (CN) 2021-02-17 EP disclosed
US-20200377460-A1 ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH, INC. (CN) 2020-12-03 US disclosed
US-20200377460-A1 ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH, INC. (CN) 2020-12-03 US disclosed
CN-110407741-A A kind of anti-inflammatory compound and its preparation and application JIAXING WEIMOU BIO TECH CO LTD 2019-11-05 CN disclosed
US-6265402-B1 ANTIINFLAMMATORY AGENTS NIKKEN CHEMICALS CO., LTD. (JP) 2001-07-24 US disclosed
EP-0924204-A1 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Nikken Chemicals Company, Limited (JP) 1999-06-23 EP disclosed
US-4186129-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, ANTICONVULSANTS SCHERING AKTIENGESELLSCHAFT (DE) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11440886-B2 Anti-inflammatory compound, and preparation and use thereof PDE4B, PDE4A, PDE7A NFKB1 116/4885BLM 3236/4885PMP22 1696/4885
US-20200377460-A1 ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF PDE4B, PDE4A, PDE7A NFKB1 116/4885BLM 3236/4885PMP22 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.